Showing results (201-210 of 216) with videos related to
Sort By:
Pageof 22
Eclinicalmedicine|October 28, 2025
Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced <i>ALK</i> <sup><i>+</i></sup> and <i>ROS1</i> <sup><i>+</i></sup> non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trialYuxiang Ma, Zhengbo Song, Jianhua Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)Hongyun Zhao, Wenxiu Yao, Xuhong Min, et al.Cell Reports. Medicine|October 4, 2025
Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b studyYuxiang Ma, Shaoyan Lin, Qun Chen, et al.Nature Communications|July 18, 2019
The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinomaShaodong Hong, Dongbing Liu, Shuzhen Luo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2024
Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b TrialShen Zhao, Huaqiang Zhou, Nong Yang, et al.Molecular Cancer Research : MCR|August 31, 2017
Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based SubtypesLi Zhang, Kenzie D MacIsaac, Ting Zhou, et al.Molecular Cancer|January 11, 2019
Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencingYaxiong Zhang, Lianpeng Chang, Yunpeng Yang, et al.Journal for Immunotherapy of Cancer|April 5, 2019
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancerYaxiong Zhang, Lianpeng Chang, Yunpeng Yang, et al.Elife|October 31, 2019
Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblastsTushar D Bhagat, Dagny Von Ahrens, Meelad Dawlaty, et al.Cancer Cell|April 24, 2026
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1<sup>G2032R</sup> resistance mutation in NSCLC: The first-in-human phase 1 trialYuxiang Ma, Jinhui Xue, Fangfang Gao, et al.Pageof 22